• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Verastem Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    6/2/25 12:01:30 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VSTM alert in real time by email
    false 0001526119 0001526119 2025-06-02 2025-06-02 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 8-K 

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the

    Securities Exchange Act of 1934

     

    Date of report (Date of earliest event reported): June 2, 2025

     

    Verastem, Inc.

    (Exact Name of Registrant as Specified in Charter)

     

    Delaware   001-35403   27-3269467
    (State or Other Jurisdiction
    of Incorporation)
      (Commission
    File Number)
      (IRS Employer
    Identification No.)

     

    117 Kendrick Street, Suite 500, Needham, MA   02494
    (Address of Principal Executive Offices)   (Zip Code)

     

    Registrant’s telephone number, including area code: (781) 292-4200

     

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading
    Symbol(s)
      Name of each exchange on which registered
    Common stock, $0.0001 par value per share   VSTM   The Nasdaq Capital Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     

     

     

     

     

    Item 7.01 Regulation FD Disclosure

     

    On June 2, 2025, the Company posted its investor webcast presentation on its website, a copy of which is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

     

    Item 9.01 Financial Statements and Exhibits

     

    Exhibit No.   Description
    99.1   Investor Webcast Presentation, dated June 2, 2025
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      VERASTEM, INC.
         
    Dated: June 2, 2025 By: /s/ Daniel W. Paterson
        Daniel W. Paterson
        Chief Executive Officer

     

     

     

    Get the next $VSTM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VSTM

    DatePrice TargetRatingAnalyst
    4/10/2025$15.00Buy
    Jefferies
    3/24/2025$7.00 → $10.00Buy
    H.C. Wainwright
    12/31/2024$13.00 → $20.00Buy
    BTIG Research
    9/30/2024$13.00Buy
    Guggenheim
    11/21/2023$27.00Buy
    BTIG Research
    9/27/2023$21.00Buy
    B. Riley Securities
    6/15/2023$24.00 → $36.00Neutral → Buy
    Mizuho
    9/7/2022$6.00Buy
    Alliance Global Partners
    More analyst ratings

    $VSTM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Jefferies initiated coverage on Verastem with a new price target

      Jefferies initiated coverage of Verastem with a rating of Buy and set a new price target of $15.00

      4/10/25 12:44:18 PM ET
      $VSTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright reiterated coverage on Verastem with a new price target

      H.C. Wainwright reiterated coverage of Verastem with a rating of Buy and set a new price target of $10.00 from $7.00 previously

      3/24/25 7:46:47 AM ET
      $VSTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BTIG Research reiterated coverage on Verastem with a new price target

      BTIG Research reiterated coverage of Verastem with a rating of Buy and set a new price target of $20.00 from $13.00 previously

      12/31/24 7:57:33 AM ET
      $VSTM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VSTM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Rowinsky Eric K bought $7,680 worth of shares (2,000 units at $3.84) (SEC Form 4)

      4 - Verastem, Inc. (0001526119) (Issuer)

      1/24/24 4:00:39 PM ET
      $VSTM
      Biotechnology: Pharmaceutical Preparations
      Health Care